Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00490516 · ClinicalTrials.gov registry record · Phase 2
ACP-104 in Acutely Psychotic Subjects With Schizophrenia
A Phase 2 study, sponsored by ACADIA Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 247
- Enrollment target
NCT00490516 is a Phase 2 study that has completed, run by ACADIA Pharmaceuticals. The registered enrollment target is 247 participants.
The verdict
NCT00490516, a Phase 2 study, has completed, sponsored by ACADIA Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 247 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled parallel-group, 6-week study, evaluating two dose levels of ACP-104 or Placebo twice a day in patients with schizophrenia who are experiencing an acute psychotic episode.
Interventions
- DRUG Placebo
- DRUG ACP-104
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 247 participants |
| Start Date | 2007-06 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00490516
The ClinicalTrials.gov registry entry for NCT00490516 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 247 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ACADIA Pharmaceuticals, which has 35 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00490516 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00490516 about?
NCT00490516 is a clinical study titled "ACP-104 in Acutely Psychotic Subjects With Schizophrenia". This is a randomized, double-blind, placebo-controlled parallel-group, 6-week study, evaluating two dose levels of ACP-104 or Placebo twice a day in patients with schizophrenia who are experiencing an acute psychotic episode.
What is the current status of trial NCT00490516?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 247 participants. The study started on 2007-06. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00490516?
The interventions under investigation include: Placebo (DRUG), ACP-104 (DRUG).
Who is sponsoring clinical trial NCT00490516?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.